Overview

Update
IPO / Stock
Went Public on Apr 17, 2014 / NASDAQ:VTL
Total Equity Funding
$203.37M in 8 Rounds from 6 Investors
Headquarters:
San Diego, CA
Description:
Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.
Categories:
Health Care, Biotechnology, Medical
Website:
http://www.vitaltherapies.com
Social:

Company Details

Update

Vital Therapies, Inc. is a biotherapeutic company focused on developing a cell-based therapy targeting the treatment of acute liver failure. Our product candidate, the ELAD® System, or ELAD, is a bio-artificial liver therapy that operates outside the body, or extracorporeal, and is designed with the proposed intent to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until liver transplant. ELAD is an allogeneic cellular therapy system incorporating our human liver-derived C3A cells contained in four hollow fiber cartridges that are combined with a single use customized disposable set and a reusable bedside unit. Data from ELAD clinical studies has shown trends that may indicate a potential to increase survival rates in patients with acute liver failure. ELAD has received orphan designation in the United States and Europe for the treatment of acute liver failure. Prior to the initiation of our ongoing Phase III clinical trial program, more than 150 subjects have received ELAD therapy in seven clinical trials and through a compassionate use program, which we believe collectively suggests a promising therapeutic profile. We are currently initiating three Phase III clinical trials in various acute liver failure conditions. In March 2013, we initiated VTI-208, a Phase III randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation. In the fourth quarter of 2013, we intend to initiate two additional Phase III randomized controlled trials, VTI-210, in 120 subjects with acute alcoholic hepatitis, and VTI-212, in 126 subjects with fulminant hepatic failure.

Funding Rounds (9) - $205.87M

Update
DateAmount / RoundValuationLead InvestorInvestors
Mar, 2014$13.93M / Private Equity0
Jan, 2014$31.98M / Private Equity0
Nov, 2012$86.15M / Private Equity0
Jun, 2012$2.5M / Debt Financing0
Feb, 2012$4.35M / Venture1
Jun, 2011$22.62M / Series D0
Jun, 2011$16.25M / Convertible Note0
Oct, 2007$28.1M / Series C4
May, 2004undisclosed amount / Venture1

Current Team (8)

Update

News (34)

Update
DateNews
Feb 8, 2016PRNewswire UK All - Translational Regenerative Medicine: Market Prospects 2016-2026
Jan 29, 2016Business Wire - DEADLINE ON MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Vital Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
Jan 29, 2016Business Wire - 2-Day Deadline Alert: Goldberg Law PC Announces Filing of Securities Class Action Lawsuit Against Vital Therapies, Inc. and Strongly Encourages Investors With Losses in Excess of $50,000 to Contact the Firm
Jan 29, 2016PRNewswire All - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Vital Therapies, Inc. of Class Action Lawsuit and Upcoming Deadline - VTL
Dec 16, 2015Business Wire - Vital Therapies, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Dec 14, 2015Business Wire - IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against Vital Therapies, Inc. and Strongly Encourages Investors to Contact the Firm
Dec 14, 2015Business Wire - INVESTOR ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Vital Therapies, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
Dec 9, 2015Business Wire - IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces Filing of Securities Class Action Lawsuit against Vital Therapies, Inc. and Strongly Encourages Investors to Contact the Firm

Offices/Locations (1)

Update
  • Headquarters

    15010 Avenue of Science

    Suite 200

    San Diego, CA 92128

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos